Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus capecitabine vs capecitabine in advanced HER2-negative breast cancer
2014-002620-26Phase 2Terminated
- Sponsor
- Incyte
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Ruxolitinib + capecitabine with Placebo + capecitabine (2 arms). Primary endpoint: Overall survival. Started Oct 2014; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-002620-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002620-26.